Firms launch an actinium-225 venture

Abstract

Isotope Technologies Munich (ITM), a German radiopharmaceutical firm, and Canadian Nuclear Laboratories (CNL) are forming a joint venture for the industrial-scale production of actinium-225 ( 225 Ac). The rare, α-emitting medical radioisotope is of interest as a precision oncology therapy. The venture, Actineer, plans to build a dedicated actinium production facility in an unspecified location. It will begin supplying 225 Ac in the interim; CNL will provide starting material for irradiation at its laboratory in Chalk River, Ontario, and ITM will process the resulting 225 Ac to pharmaceutical-grade material. CNL operates a national laboratory at Chalk River on behalf of Atomic Energy of Canada.